Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

Phase 2 Terminated 12 enrolled Dana-Farber Cancer Institute Brigham and Women's Hospital · collab Massachusetts General Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this trial is to look at how elderly women (70 years of age or older) with newly diagnosed ovarian, peritoneal, or fallopian tube cancer manage six cycles of carboplatin and paclitaxel, what side effects they experience, and how their cancer reacts or responds to standard carboplatin and paclitaxel chemotherapy.

Timeline

Start: 2006-04
Primary completion: 2008-04
Completion: 2010-04

Outcome

Outcome not reported

Stopped: “Early closure based on audit by study investigators after 3 patients died on study.”

Publications

Results Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecol Oncol. 2009 Feb;112(2):394-9. doi: 10.1016/j.ygyno.2008.10.015. Epub 2008 Dec 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Paclitaxel	Small molecule	175 mg/m2	Intravenous